INTRODUCTION
The mevalonate (MVA) pathway produces sterols, especially cholesterol, which is essential for cell membrane structure, bile acids, and steroid hormones (Goldstein and Brown, 1990) . Moreover, the MVA pathway is also known to synthesize isoprenoids, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which are essential sources of protein prenylation (Casey, 1992) . In particular, prenylation comprises a post-translational process that modifies a multitude of proteins involved in protein synthesis and glycosylation, intracellular signaling, gene expression, and cell growth (Casey, 1992; Goldstein and Brown, 1990 ). In addition, 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase (HMGCR), a rate-limiting enzyme in the MVA pathway, catalytically converts HMG-CoA to MVA and is further repressed via negative feedback regulation (Goldstein and Brown, 1990) .
As the MVA pathway affects various metabolic pathways, inhibitors of HMGCR, also known as statins, have been extensively used in the clinic as an effective treatment for hypercholesterolemia, in addition to being considered as potential treatments for certain features of cardiovascular disease and hepatic disorders (Kamal et al., 2017; Wadhera et al., 2016) . However, accumulating data indicate that the usage of statins has certain unexpected cholesterol-independent pleiotropic effects, such as increased risk of new-onset diabetes or muscle disorders (Thompson et al., 2003; Zaharan et al., 2013) . Skeletal muscle-specific HMGCR knockout mice also exhibited similar symptoms (Osaki et al., 2015) . Furthermore, disruption of HMGCR in the liver, the major target organ for statin metabolism, has been reported to cause liver steatosis and death (Nagashima et al., 2012) . These phenomena are thought to be caused by insufficient intermediate products generated in the MVA pathway (Bang and Okin, 2014; Brault et al., 2014) and suggest that HMGCR is important for mammals and plays a different role in each organ.
Obesity, defined as an increase in adipose tissue mass, is thought to be highly related to lipid metabolism diseases, such as hypercholesterolemia (Fasshauer and Bluher, 2015; Lackey and Olefsky, 2016) . In addition, adipose tissue is known to be the major organ for cholesterol storage, thus serving an important function in regulating systemic cholesterol metabolism (Bays et al., 2013; Krause and Hartman, 1984) . However, the role of the MVA pathway in adipose tissue remains completely unknown. Previous studies have shown that MVA-derived metabolites, such as FPP and GGPP, serve as endogenous regulators of adipocyte function (Goto et al., 2011; . Moreover, MVA pathway-related gene expression is partially enhanced in the adipose tissue of an obese/diabetic mouse model Yu et al., 2011) . These results reveal that isoprenoids may play an important role in the regulation of adipose tissue function. Thus, to further clarify the detailed role of isoprenoids in adipose tissue function, we generated adipose-specific MVA pathway-disrupted (aKO) mice through specific knockout of HMGCR in adipose tissue. Here, we show that the MVA pathway in adipocytes is both necessary and sufficient to maintain adipocyte survival, which in turn further influences systemic homeostasis.
RESULTS aKO Mice Show Systemic Lipodystrophy
To study the role of the MVA pathway ( Figure 1A ) in adipose tissues, we generated aKO mice using the Cre-loxP system. The floxed HMGCR mice, designed as shown in Figure S1A , were crossed with adiponectin-Cre mice (Eguchi et al., 2011) . HMGCR knockout alleles were observed only in the genomic DNA extracted from white adipose tissue (WAT) and brown adipocyte tissue (BAT) and not in the DNA from other tissues in heterozygous aKO mice ( Figure S1B ).
Eight-week-old male (Figures 1, 2 , and 3) and female mice ( Figure S2 ) were used. The body weights of aKO mice of both genders were higher than those of control (Ctrl) mice ( Figures 1B and S2A ). Whole-body MRI scanning showed that fat mass was drastically decreased, whereas lean mass was slightly increased in aKO mice (Figures 1C and S2B) . As shown in Figure 1D , we observed that aKO mice lost almost all fat pads, including inguinal WAT (iWAT), epididymal WAT (eWAT), and BAT. Furthermore, compared with Ctrl mice, a very limited number of lipid-laden adipocytes was observed in adipose tissues (iWAT, eWAT, and BAT) in aKO mice ( Figure 1E ). Consistent with the appearance of WAT and BAT, the tissue weight and levels of plasma adipokines including adiponectin and leptin were extremely reduced in aKO mice . Although the consumption of a high-fat diet (HFD) reversed the difference in body weight gain between the two genotype groups ( Figure S3A ), this appeared to mainly result from increases of fat weight in the Ctrl group rather than from lipodystrophy amelioration in the aKO group ( Figures S3B-S3E ). These results suggest that HMGCR in the adipose tissue plays a critical role in the maintenance of adipose mass and adipokine levels.
aKO Mice Exhibit Severe Diabetes
Food intake and water consumption in aKO mice were obviously higher than those in Ctrl mice (Figures 1I, 1J, S2F, and S2G) . Moreover, the non-fasting plasma glucose and insulin levels were markedly enhanced in aKO mice in both the normal diet (ND) ( Figures 1K, 1L , S2H, and S2I) and HFD (Figures S3F and S3G) conditions, suggesting that glucose metabolism was disrupted in aKO mice. The glucose tolerance test (GTT) showed that plasma glucose levels were significantly higher in aKO mice after oral glucose administration, and the area under the curve also showed that glucose tolerance was reduced in aKO mice ( Figure 1M ). In the insulin tolerance test (ITT), plasma glucose levels were effectively reduced after insulin injection in Ctrl mice but not in aKO mice ( Figure 1N ). Female mice also showed similar results in GTT and ITT (Figures S2J and S2K) . These results clearly show that ablation of HMGCR in adipose tissues induced lipodystrophy accompanied by severe dysfunction of glucose metabolism.
aKO Mice Develop Ectopic Lipid Deposition in the Liver
Both male and female aKO mice had enlarged liver (Figures 2A and S2L, Table S2 ). Moreover, many bubble-like areas were found in liver sections of aKO mice stained with hematoxylin and eosin (H&E) (Figure 2A ). Oil red O staining indicated obviously increased lipid droplets in aKO compared with Ctrl mice (Figure 2A ). Consistent with this finding, hepatic triglyceride (TG) accumulation in aKO mice was enhanced (Figures 2B and S2M) . As shown in Figure 2C , hepatic lipid-synthesis-related genes, such as sterol regulatory element-binding protein 1 (Srebf1), fatty acid synthase (Fasn), and peroxisome (I and J) Food intake (I) and water consumption (J) of Ctrl and aKO mice measured from 14 to 32 weeks of age. (K and L) Plasma glucose (K) and insulin (L) levels analyzed in 32-week-old Ctrl and aKO mice. (M) GTT in Ctrl and aKO mice was assessed at 16 weeks of age. (N) ITT in Ctrl and aKO mice was assessed at 18 weeks of age. All mice were male and fed a normal diet (ND). Bars represent the mean G SE. (n = 6-8). Significant differences were determined by Student's t test compared with Ctrl: *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2. proliferator-activated receptor gamma (Pparg), were highly expressed in aKO compared with Ctrl mice, whereas very limited changes were observed in lipid-oxidation-related gene expression, including that of acyl-coenzyme A oxidase 1 (Acox1), carnitine palmitoyltransferase IA (Cpt1a), and peroxisome proliferator-activated receptor alpha (Ppara). These results suggest that increased hepatic lipid accumulation in aKO mice might mainly result from the up-regulation of lipid biosynthesis. In addition, hepatic liver glycogen showed a 2.5-fold increase in aKO mice compared with Ctrl mice, and hepatic gluconeogenesis-related gene expression, such as that of phosphoenolpyruvate carboxykinase (Pck1), glucose-6-phosphatase (G6pc), and fructose-1,6-bisphosphate (Fbp1), was also higher in aKO compared with Ctrl mice (Figures 2D and 2E) . These data suggest that adipose-disrupted HMGCR possibly affected hepatic glucose metabolism.
The activities of plasma glutamic-oxaloacetic transaminase (GOT) and glutamic-pyruvic transaminase (GPT), the main hepatic injury markers, were significantly elevated in aKO mice compared with Ctrl mice ( Figures 2F and  S2N ). To determine whether aKO mice exhibited progressive hepatic fibrosis and inflammation, associated gene expression levels were evaluated. The expression of inflammatory marker genes, such as tumor necrosis factor alpha (Tnf), EGF-like module-containing mucin-like hormone receptor-like 1 (Adgre1, also known as F4/ 80), and integrin, alpha X (Itgax, also known as CD11c), was increased in aKO mice ( Figure 2G ). Moreover, expression of fibrosis-related genes including fibronectin (Fn1); transforming growth factor b (Tgfb); collagen, type I, alpha 1 (Col1a1); and alpha-actin-2 (Acta2, also known as alpha smooth muscle actin) was also increased in the liver of aKO mice ( Figure 2H ). These results indicate that HMGCR ablation in adipose tissue induced abnormal liver function with potential progression toward cirrhosis. 
Adipose-Specific Disruption of HMGCR Alters the Pattern of Energy Expenditure
Although locomotor activity was significantly reduced in aKO mice ( Figures 2I and S2O) , the oxygen consumption rate was increased compared with Ctrl mice ( Figures 2J and S2P ). The respiratory exchange ratio (RER) was decreased in aKO mice in the dark state, suggesting that aKO mice prefer to use fatty acid as an energy source compared with Ctrl mice (Figures 2K and S2Q) . Consistent with the RER results, we found that plasma b-hydroxybutyric acid (b-HB), a type of ketone body metabolized from fatty acid, was up-regulated, accompanied by an increase of several lipids, such as TG, free fatty acid (FFA), and cholesterol (Figures 3L and S3R) . Thus, these data indicate that adipose-specific HMGCR ablation disrupts lipid and energy metabolism, as well as locomotor activity.
Thiazolidinedione Improves Glucose-Metabolic Disorders without Rescuing Adipose Tissue Mass in aKO Mice
A previous study reported that MVA metabolites could modulate PPARg activity, which plays a central role in adipocyte differentiation (Goto et al., 2011) . Therefore, to examine whether lipodystrophy in aKO mice resulted from a reduction of PPARg activity, we next orally administered a synthetic PPARg agonist (pioglitazone [Pio], 30 mg/kg/day) to the mice for 10 weeks. Although Pio treatment reduced body weight gain and enhanced fat mass in aKO mice, the lack of adipose tissue in aKO mice was not improved ( Figures S4A-S4C ). Furthermore, Pio treatment further aggravated hepatomegaly, hepatic TG accumulation, and enhanced plasma GOT and GPT activities in aKO mice ( Figure S4D ). Pio treatment increased the plasma adiponectin level and decreased the plasma leptin level in Ctrl mice but had no such effects in aKO mice (Figures S4E and S4F) . Although Pio failed to rescue the fat mass, the hyperphagia, hyperdipsia, hyperglycemia, and hyperinsulinemia were ameliorated by Pio treatment in aKO mice ( Figures S4G-S4J ). Taken together, these results indicate that PPARg agonist treatment improved several metabolic disorders independently of adipose tissue function in aKO mice, suggesting that HMGCR-mediated lipodystrophy was minimally associated with the deficiency of MVA-derivative PPARg ligands.
Implantation of Adipose Tissue Reverses Diabetic Consequences in aKO Mice
Next, to investigate whether metabolic abnormalities in aKO mice were related to lipodystrophy, we performed WAT implantation. At 16 weeks after implantation, the fat grafts were successfully implanted subcutaneously and their weight was enhanced by approximately 1.8-fold compared with the initially transplanted fat weight ( Figure S5A ). The transplanted fat pads exhibited blood vessel formation and showed normal histology ( Figures S5B and S5C ). At six weeks after surgery, sham-operated (Sham) mice were significantly heavier than Ctrl and transplanted (Transplant) mice, which showed no significant difference in body weight ( Figure 3A) . Notably, however, fat implantation only resulted in mild recovery in plasma leptin and adiponectin levels ( Figures 3B and 3C ). Furthermore, we found that the enhanced food intake and water consumption in Sham mice were completely reversed by fat transplantation (Figures 3D and 3E ). In addition, glucose metabolic disturbances including hyperglycemia, glucose intolerance, and insulin resistance in aKO mice were almost entirely reversed by fat transplantation (Figures 3F-3I ). These results demonstrated that the severe diabetic symptoms occurring in adipose-specific HMGCR knockout were mainly due to WAT deficiency.
Adipose Tissue Implantation Reverses Defects of Hepatic Metabolism in aKO Mice
We next addressed whether the defective hepatic phenomena in aKO mice could be improved through fat transplantation. As shown in Figure 4A , the abnormal liver appearance and hepatic histology in Sham mice were reversed in Transplant mice. Consistent with this finding, hepatic TG accumulation levels were normalized by fat transplantation in aKO mice ( Figure 4B ). The gene expression associated with lipid Figure 4C ). Furthermore, fat implantation also reversed the abnormalities in both total hepatic glycogen levels and gluconeogenesis-related gene expression in aKO mice ( Figures 4D and 4E) . These results suggest that both abnormal hepatic lipid and glucose metabolism in aKO mice mainly resulted from insufficient WAT. Consistent with liver appearance and morphological variation, the increased plasma GOT and GPT activities in the Sham group were both reduced to the levels in the Ctrl group by fat transplantation ( Figure 4F ). Moreover, inflammation-and fibrosis-related gene expression were increased in the Sham group, whereas these changes were significantly reversed in the Transplant group ( Figures 4G and 4H ). These results suggest that fat implantation likely improved hepatic inflammation and fibrosis in aKO mice.
Fat Transplantation Partially Improves the Pattern of Energy Expenditure in aKO Mice
Notably, the decreased locomotor activity was completely reversed by fat implantation in aKO mice (Figure 4I) . As shown in Figure 4J , Sham mice showed higher oxygen consumption than Ctrl mice, whereas this enhancement was depressed in Transplant mice. Furthermore, based on the results of RER, the energy source was shifted from lipid to carbohydrate usage in aKO mice by fat transplantation ( Figure 4K ). Consistent with this finding, the increase in plasma b-HB level was reversed by fat implantation in aKO mice as well ( Figure 4L ), indicating that the disrupted lipid metabolism in aKO mice was possibly improved by fat transplantation. As expected, adipose tissue implantation reversed the up-regulation of plasma lipid levels in aKO mice ( Figure 4L ). These findings support that the disrupted metabolism and activity pattern in aKO mice might be largely due to an insufficiency of systemic adipose tissue.
Inadequate HMGCR Causes Adipocyte Death In Vitro
To examine why HMGCR deficiency causes lipodystrophy, we used lovastatin (Lova) to inhibit HMGCR activity in differentiated 3T3-L1 adipocytes. The stained lipid droplets and intracellular TG levels were obviously decreased in Lova-treated 3T3-L1 adipocytes, whereas these phenotypic variations were reversed in the presence of MVA or GGPP but not squalene or FPP ( Figures S6A and S6B ). Moreover, HMGCR inhibition extensively decreased cell viability, and this effect was prevented by MVA and GGPP ( Figure S6C ), as evidenced by the number of Hoechst-stained nuclei ( Figure S6A ). In addition, we isolated primary preadipocytes from the WAT of an HMGCR f/f mouse (primary WAT). Consistent with the other findings, in differentiated primary WAT cells, we found that the Lova-induced reduction in lipid accumulation was reversed by co-treatment with MVA or GGPP but not squalene or FPP ( Figures 5A and 5B ). Furthermore, the Lova-mediated reduction of adipocyte viability was ameliorated in the presence of MVA or GGPP ( Figure 5C ). Therefore, Lova-mediated inhibition of the MVA pathway leads to decreased adipocyte viability. Interestingly, MVA and GGPP but not FPP could completely prevent Lova-induced adipocyte death ( Figures 5A-5C and S6A-S6C). However, treatment with isopentenyl pyrophosphate (IPP) alone failed to avert Lova-induced reduction of both lipid accumulation and Hoechst-stained nuclei, but successfully rescued these processes when combined with FPP in primary WAT cells ( Figure S7 ). Therefore, both IPP, enzymatically synthesized from MVA, and FPP are required for GGPP synthesis.
To exclude the possibility of adipocyte death caused by cholesterol deficiency, cholesterol was added to Lova-treated primary WAT cells. As shown in Figures S8A and S8B , the Lova-decreased lipid accumulation and Hoechst-stained nuclei in primary WAT cells could not be restored to normal levels by cholesterol treatment. We also fed aKO mice with a high-cholesterol diet (HCD) for 6 weeks. Although the plasma cholesterol level in HCD-fed aKO mice was substantially higher than that in ND-fed aKO mice ( Figure S8C ), adipose tissue mass and plasma adipokine levels in HCD-fed aKO mice did not recover to normal levels ( Figures S8D-S8G ). These results clearly suggest that adipocyte death resulting from the inhibition of the MVA pathway was most likely not related to cholesterol insufficiency. Next, to mimic the HMGCR knockout in adipocytes, we stably induced tamoxifen (Tamo)-activated Cre in primary WAT cells (primary Ert2Cre+ WAT). As shown in Figure 5D , Tamo treatment for 48 hr knocked out the Hmgcr gene in a concentration-dependent manner in primary Ert2Cre+ WAT cells. In particular, mRNA expression levels of Hmgcr in differentiated primary Ert2Cre+ WAT cells showed concentration-dependent reduction by Tamo treatment ( Figure 5E ). As we observed that Adipoq expression levels in these cells were drastically increased from 4 days after differentiation induction ( Figure 5F ), we assumed that the knockout program was triggered from D4 to D6. Differentiated primary Ert2Cre+ WAT cells were then treated with 10 mM Tamo and simultaneously with the MVA metabolites, as shown in Figure 5G . The stained lipid droplets and intracellular TG levels were obviously decreased in Tamo-treated adipocytes, whereas these phenotypic variations were reversed in the presence of MVA or GGPP but not squalene or FPP ( Figures  5G and 5H) . Moreover, Hoechst staining of nuclei and the cell viability assay showed that HMGCR knockout extensively reduced the number of adipocytes and that this effect was prevented by MVA or GGPP treatment ( Figures 5G and 5I) . These results suggested that the disruption of the MVA synthesis pathway caused adipocyte death, which may be have been due to the lack of GGPP.
Apoptosis May Be Associated with HMGCR Deficiency-Induced Adipocyte Death
We observed that smaller cells and cell debris, characteristic of apoptotic cell death, occurred in the disrupted HMGCR adipocytes upon both genetic and pharmacological manipulation ( Figures 6A and S9A) . Thus, we stained cells with annexin V-fluorescein isothiocyanate (annexin V) and propidium iodide (PI), which indicate early and late apoptosis, respectively. In the Lova-treated 3T3-L1 adipocytes, the numbers of cells stained with annexin V and PI were increased, and this effect was reversed by co-treatment with MVA and GGPP ( Figure S9B ). Consistent with this finding, Lova-treated primary WAT exhibited almost identical morphological changes ( Figure 6B ). In addition, Tamo-induced genetic ablation of HMGCR increased the numbers of annexin V-and PI-stained primary Ert2Cre+ WAT cells, and these phenomena were ameliorated by the addition of MVA or GGPP but not squalene or FPP ( Figure 6C ). Consistent with the results described above, expression of the anti-apoptotic gene B-cell lymphoma 2 (Bcl-2) was decreased, whereas that of the apoptotic genes Bcl-2-associated X protein (Bax) and caspase 3 (Casp3) was increased in HMGCR-knockout adipocytes ( Figure 6D ). Conversely, these apoptosis-related gene expression changes were dramatically reversed by the administration of MVA or GGPP ( Figure 6D ). These results indicate that the MVA biosynthesis pathway, especially GGPP, may serve an important role to control adipocyte viability by regulating apoptosis.
GGPP Plays an Essential Role in Maintaining Adipocyte Survival by Regulating Apoptosis
To further confirm whether GGPP is the key metabolite necessary for adipocyte survival, we treated primary WAT cells with zoledronate (Zol) to inhibit GGPP synthesis (Guo et al., 2007; No et al., 2012) . Zol treatment significantly decreased the lipid accumulation, number of Hoechst-stained nuclei, and cell viability ( Figures  7A-7C ). However, these Zol-induced effects were completely reversed by GGPP addition and only partially reversed by FPP addition, indicating that GGPP depletion caused adipocyte death ( Figures 7A-7C ). Moreover, Zol-induced apoptosis, as confirmed by the apoptosis staining assay and apoptosis-related gene expression, was compromised by supplementation of GGPP ( Figures 7D and 7E ).
Next, GGPP synthase (Ggps) was genetically down-regulated by infection of adenovirus encoding Ggps-specific short hairpin RNA (shGGPS) in 3T3-L1 adipocytes overexpressing the coxsackievirus-adenovirus receptor ( Figure S10A ). Compared with the control group (shlacZ), all types of shGGPS (shGGPS#1, #2, and #3) decreased the expression of Ggps and the anti-apoptotic gene Bcl-2 and enhanced the expression of the apoptotic genes Bax and Casp3, suggesting that Ggps knockdown induced apoptosis in differentiated adipocytes (Figures S10B and S10C). Next, we performed a GGPP add-back experiment to prove that GGPP depletion is the main driver of apoptosis. As shown in Figures S10D-S10F, shGGPS caused adipocyte death, whereas GGPP addition could prevent it. Furthermore, the results of apoptosis staining and relative gene expression showed that GGPP supplementation ameliorated shGGPS-induced adipocyte apoptosis ( Figures 7F and 7G) . These findings indicate that GGPP is the key metabolite in the MVA pathway, which is indispensable for adipocyte survival, possibly through a mechanism that modulates apoptosis.
DISCUSSION
The MVA biosynthesis pathway produces not only sterols but also non-sterols termed isoprenoids, such as FPP and GGPP (Casey, 1992; Goldstein and Brown, 1990) . Isoprenoids have been shown to play an important role in controlling cell metabolism and viability for both cancer and normal cells, such as fibroblasts, immune-related cells, and neuronal cells (Moutinho et al., 2017; Mullen et al., 2016; Tristano and Fuller, 2006; van der Burgh et al., 2014) . Here, we established HMGCR deficiency models in vivo and in vitro that indicated that the MVA pathway is essential for adipocyte survival, and that suggest that GGPP may contribute in controlling adipocyte death by regulating apoptosis.
In humans, lipodystrophy can broadly be classified into genetic and acquired types (Hegele et al., 2007) . Both these lipodystrophies frequently display some metabolic phenomena, such as hepatic disorders, abnormal glucose metabolism, and dyslipidemia (Hegele et al., 2007; Ludtke et al., 2005) . Consistent with phenotypic variations resulting from lipodystrophy in humans, in the current study, aKO mice exhibited lipodystrophic phenotypes along with hepatomegaly, severe diabetic symptoms, and abnormal lipid metabolism. Furthermore, these lipodystrophy-related metabolic changes have also been confirmed in different lipodystrophic mouse models, such as the A-ZIP/F1 mouse, which is the typical fatless mouse model (Moitra et al., 1998) , or in mice with double knockout for insulin receptor and insulin-like growth factor 1 Softic et al., 2016) . Consistent with these lipodystrophic model mice, aKO mice also presented a dramatic decrease in both WAT and BAT mass. However, Guerra et al. (2001) have shown that BAT-atrophic mice exhibit a diabetic phenotype without insulin resistance. These results suggest that at least the diabetic phenotype occurring in aKO mice mainly resulted from atrophy of WAT but not BAT.
The symptoms of lipodystrophic patients or mouse models have largely been reported; however, the phenomena differ based on the respective cause and its mechanisms. In humans, patients with acquired-type lipodystrophies have almost normal weight or are underweight, whereas genetic-type lipodystrophies have different effects on body mass index variation ranging from underweight to overweight according to the mutant gene (Hegele et al., 2007) . In comparison, lipodystrophic mice generated by PPARg disruption exhibit a decrease in body weight gain despite an increase of food intake, energy expenditure, and activity (Jones et al., 2005) . The A-ZIP/F1 mouse displayed an obviously enhanced body weight and food intake with no significant variations in energy expenditure and activity (Guo et al., 2012; Moitra et al., 1998) . Conversely, in the current study, aKO mice showed increased body weight, food intake, and energy expenditure but decreased locomotor activity. Thus, lipodystrophic phenotypes, such as body weight, food intake, or energy expenditure, possibly vary between cases.
PPARg mutations represent one genetic type of lipodystrophy (Hegele et al., 2007) . Our previous study reported that the MVA-derived metabolite, FPP, acts as a PPARg ligand (Goto et al., 2011) , suggesting that lipodystrophy in aKO mice possibly results from deficiency of a PPARg ligand. However, Pio treatment failed to reverse the lipodystrophy in aKO mice, whereas it partially improved diabetic phenotypes. In addition, Pio administration significantly increased liver weight and hepatic lipid accumulation but decreased body weight in aKO mice. It has been reported that rosiglitazone treatment improved the glucose metabolism but enhanced liver weight and hepatic lipid accumulation in A-ZIP/F1 mice (Gavrilova , 2003) . In contrast, in the case of patients with familial partial lipodystrophy, thiazolidinedione (TZD) treatment improved not only diabetic symptoms but also liver disorders such as steatosis and fibrosis (Brown et al., 2016) . It is possible that the improved liver function with TZD treatment is due to TZDinduced adipocyte differentiation and proliferation, which helps to reverse the excess hepatic lipid storage associated with insufficient adipose tissue mass (Chao et al., 2004) . Combined with these results, our findings suggest that without adequate functional adipose tissue, the liver in aKO mice may constitute the primary and major target organ of TZD action, which is related to systemic glucose and lipid metabolism.
Although local cholesterol deficiency, or that of its metabolites, might contribute to MVA pathway inhibition-induced lipodystrophy in aKO mice, many reports disagree with the cholesterol contribution in lipodystrophy. Severe genetic hypocholesterolemia has been found not to be associated with fat mass loss in humans (Tanoli et al., 2004) . Moreover, in the present study, even though the plasma cholesterol level was initially higher in aKO mice and was boosted by HCD, elevated plasma cholesterol seemed to be unable to restore the adipose tissue mass. Consistent results could be found with HMGCR-disrupted adipocytes treated with cholesterol. Although the cause of lipodystrophy in aKO mice seems to weakly relate to cholesterol deficiency, the incapability of de novo steroid synthesis was not completely excluded. For instance, in adipocytes, 27-hydroxycholesterol has been identified as one of the major products synthesized de novo from cholesterol by Cyp27a1. However, in mice that were deprived of Cyp27a1, no differences in WAT and body weight gain were observed, when compared with wild-type mice (Li et al., 2014) . Although further investigation is needed, these results indicate that deficiency of cholesterol, or that of its metabolites, plays a minor causative effect in lipodystrophy in aKO mice.
Notably, both lipodystrophy and obesity have been shown to exhibit several similar metabolic characteristics (Hegele et al., 2007; Ludtke et al., 2005) , suggesting that adipose tissue plays an important role in metabolic homeostasis. Previous reports demonstrated that implantation of adipose tissue reversed the diabetic symptoms in A-ZIP/F1 mice . Similarly, the present results showed that adipose tissue implantation led to dramatic recovery in all metabolic disorders in aKO mice. These phenotypic effects may have been caused by several mechanisms. First, transplanted fat grafts functionally secrete adipokines, such as adiponectin and leptin, which may contribute to the metabolic improvement. Yamauchi et al. (2001) reported that lipodystrophy-induced insulin resistance was completely reversed by combined treatment of adiponectin and leptin. In addition, it has been found that transplantation of leptindeficient adipose tissue only minimally improved lipodystrophy-related metabolic abnormalities in A-ZIP/ F1 mice (Colombo et al., 2002) . Colombo et al. (2002) also showed that the contribution of fat transplantation to plasma adiponectin is very low and that leptin treatment improved metabolism without any changes in adiponectin levels. Consistent with this finding, leptin treatment and overexpression of leptin also yielded an improvement in glucose metabolism and hepatic lipid accumulation in Srebp-1c Tg and A-ZIP/F1 mice, respectively (Ebihara et al., 2001; Shimomura et al., 1999) . These observations suggest that leptin is possibly a major adipokine required for the regulation of glucose and lipid metabolism when adipose tissue is lacking. Second, implanted fat grafts allow the storage of lipids such as FFA, cholesterol, and TG. reported that at 13 weeks after transplantation in A-ZIP/F1 mice, the total weight of transplanted fat increased by approximately 1.4-fold, and that the improvement of metabolic disorders was dose dependent with transplanted fat mass. In addition, low-mass fat implantation also ameliorated the disruption of glucose and lipid metabolism without any increase of leptin . Furthermore, TZD improved hepatic and diabetic disorders in patients with lipoatrophy concomitant with enhanced adipose tissue mass (Brown et al., 2016) . In the present study, both transplanted fat pad mass and adipocyte size were enhanced, indicating that the recovered capacity for storage of lipids in adipose tissue may contribute to the improvement of metabolic disorders caused by lipodystrophy. Moreover, fat transplantation also enhanced the increase of plasma leptin in aKO mice by 14-fold, despite an overall recovery to only 35% of the level of Ctrl mice. However, whether this enhanced plasma leptin level is sufficient to repress the abnormal metabolism in aKO mice remains unclear and requires further investigation.
The MVA pathway has been implicated in multiple aspects of the cell cycle including cell differentiation, survival, and growth (Bonetti et al., 2003; Demierre et al., 2005) . For example, it has been reported that the MVA pathway is essential for regulation of the proliferation and growth of vascular smooth muscle cells (Bonetti et al., 2003) . Several cancers, such as colorectal cancer and melanoma, were inhibited by administration of HMGCR inhibitors (Demierre et al., 2005) . These reports suggested that MVA pathway inhibition is possibly linked to programmed cell death, i.e., apoptosis (Bonetti et al., 2003; Demierre et al., 2005; Wong et al., 2002) . Similarly, in adipocytes, we found that a disrupted MVA pathway caused cell death that at least partially involved isoprenoid-regulated apoptosis. The possible involvement of coenzyme Q10 (CoQ) deficiency or impaired GGPP-related prenylation has been reported in several cell lines, such as myocytes, hepatocytes, or tumor cells, as the underlying mechanism of HMGCR inhibition-induced apoptosis (Alizadeh et al., 2017; Auer et al., 2016; Demierre et al., 2005; Tavintharan et al., 2007) . However, CoQ supplementation did not prevent Lova-induced adipocyte death, and treatment of GGTI2133 and Y27632, inhibitors of geranylgeranyl transferase and Rho-associated protein kinase, respectively, did not alter the outcome of adipocyte death (data not shown), indicating that the relationship between GGPP and apoptosis is an unexpected mechanism. Although detailed information about the mechanism remains unclear, we urge persistent users of statins to take the findings of this study into consideration. Interestingly, supplementation with FPP failed to prevent HMGCR inhibition-induced cell death, although GGPP is enzymatically synthesized from FPP. This may have occurred because IPP deficiency, resulting from HMGCR impairment, could not convert FPP to GGPP (Demierre et al., 2005; Park et al., 2014) , which was also confirmed in the present report. In addition, Pajvani et al. (2005) demonstrated that adipose-targeted apoptosis causes lipodystrophy. These results may underlie the strong relationship between lipodystrophy and apoptosis in aKO mice.
Obesity, a complex multifaceted disease based on an increased WAT mass, is associated with an enhanced risk for other metabolic diseases such as diabetes mellitus (Kusminski et al., 2016) . Notably, adipocyte turnover is extremely low in humans, such that the adipocytes replace themselves in about 10 years, whereas most other cell types only require from several days to a few months (Shamir et al., 2016; Spalding et al., 2008) . It appears that adipocyte death is rarely triggered, although the detailed mechanisms remain unclear. Previous reports have demonstrated that intracellular GGPP levels and Ggps expression levels increase during adipocyte differentiation. Moreover, Ggps gene expression levels were enhanced in WAT in both HFD-induced and ob/ob obese mouse models, as well as in diabetic db/db mice Yu et al., 2011) , suggesting that GGPP may play a major role in adipocyte function. In the present study, we show that HMGCR deficiency contributed to lipodystrophy, and that this may be associated with GGPP-related regulation of apoptosis. Here, we hypothesize that GGPP is a key MVA-derived metabolite involved in maintaining adipocyte survival. Upon adipocyte expansion and maturation, increased GGPP levels may protect adipocytes from apoptosis. This hypothesis potentially suggests that adipocyte turnover may be regulated through modulation of the MVA pathway. However, further investigation is needed to clarify this hypothesis.
Overall, our results demonstrate that adipose-specific disruption of the MVA pathway causes lipodystrophy and results in several metabolic variations such as abnormal glucose and lipid metabolism, as well as hepatic disorders. Here, we propose one possible mechanism wherein GGPP deficiency in adipocytes underlies these phenotypes. Moreover, the lipodystrophy mediated by MVA pathway inhibition possibly resulted from GGPP deficiency-induced adipocyte apoptosis. Our hypothesis provides insight regarding the potential mechanisms to control adipocyte turnover through regulation of the MVA pathway, as a potential therapeutic strategy for obesity. Furthermore, these findings might provide useful information for the clinical application of statin.
Limitations of the Study
We showed that GGPP deficiency induced apoptosis in adipocytes, suggesting that the MVA pathway is critical for adipocyte survival. However, owing to technical limitations, we could not quantify GGPP in adipocytes and adipose tissue. Therefore, we do not know the exact amount of GGPP required to ensure adipocyte survival. A main concern is regarding why blood circulation could not provide sufficient MVA or GGPP to compensate the HMGCR deficiency-induced lipodystrophy. Furthermore, we do not know whether the role of inhibited HMGCR in human adipocyte is consistent with that shown in the present study, because we used a mouse and mouse-derived cell models. Although we cannot provide any information about these issues, we aim to address such important issues in future studies to better understand the physiological function of GGPP.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. 
Reagents
Mevalonic acid, IPP, FPP, GGPP and zoledronate were purchased from Sigma (St. Louis, MO, USA). Lovastatin, tamoxifen, and pioglitazone were obtained from Tokyo Kasei (Tokyo, Japan). Other chemicals were purchased from Sigma, Nacalai Tesque (Kyoto, Japan), or Wako Pure Chemicals (Osaka, Japan).
Animals
All animal experiments and maintenance were in accordance with the guidelines of the Kyoto University Animal Care Committee (approval code 28-49). Five-week-old C57BL/6 male mice were purchased from Japan SLC (Hamamatsu, Japan). All mice were housed at 23 ± 1 °C and maintained on a 12-h light/dark cycle. In all of the experiments, mice were fed a commercial chow diet (CRF-1, Charles River Japan, Kanagawa, Japan) until 8 weeks of age, and then the mice were randomly divided into groups for experiments.
Cell lines
3T3-L1 murine preadipocytes were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 100 U/ml penicillin as the growth medium at 37°C in 5% CO2.
Primary adipose cells were prepared as in a previous study (Aune et al., 2013) . Primary adipose cells were isolated from WAT of male HMGCR f/f mice and infected with ERT2-Cre expression retrovirus, which was kindly provided by Prof. Yasutomi Kamei (Kyoto Prefectural University, Kyoto, Japan). After 24 h of infection, cells were selected by 2.5 μg/ml puromycin for 1 week and used for cell culture experiments.
Mouse Phenotype Assessment
For examining the influence of adipose-specific HMGCR on metabolic state, the mice were fed a chow diet and sacrificed at 32 weeks of age. In the high fat diet (HFD) treatment experiment, mice were fed HFD containing 60% kcal fat (HFD, Research Diet, New Brunswick, NJ, USA) for 20 weeks. Pio treatment was administered for 10 weeks. In the high cholesterol diet treatment experiment, 18-week-old mice were fed the control diet (AIN-93M, Oriental Yeast Co., Tokyo, Japan) or AIN-93M, containing 1% (w/w) of cholesterol, for 6 weeks. To perform the GTT assay, mice were fasted for 6 h and a blood sample was taken from the mouse tail vein (0 min point). Subsequently, mice were orally treated with glucose solution (2 g of glucose/ 10 ml of sterile phosphate-buffered saline, 10 ml/g body weight) and blood samples were collected at different time points (15, 30, 60, and 120 min) . For analysis of ITT, blood samples were collected from the mouse tail vein (0 min point) and the mice were then intraperitoneally injected with insulin solution (0.1 U of insulin/ml of sterile phosphate-buffered saline, 10 μl/g body weight) after fasting for 6 h. The blood samples were taken at 15, 30, 60, and 120 min. The oxygen consumption was measured using an indirect calorimetric system (Oxymax Equal Flow 8 Chamber/Small Subject System; Columbus Instruments, Columbus, OH, USA) equipped with an eight-chamber airtight metabolic cage. The RER was calculated by dividing the CO2 production by the O2 consumption.
The locomotor activity was measured using an Actimo-S system (Bio Research Centre, Nagoya, Japan). For both oxygen consumption and locomotor activity measurement, mice were acclimatized to the individual experiment-specific cages for 2 hours prior to the experiment and measurement was performed from 15:00 (ZT8) to the next day at 11:00 (ZT4) in a 12-h light/dark cycle condition. Body composition was scanned using an EchoMRI 3-in-1 system (Hitachi, Tokyo, Japan), in accordance with the manufacturer's instructions.
Strategy and Generation of aKO mice
The floxed HMGCR mice (HMGCR f/f) were generated by Unitech Co. (Chiba, Japan). Adipoq-Cre BAC transgenic mice (RRID: IMSR_JAX:010803) were purchased from Jackson Laboratory (Bar Harbor, ME, USA). To generate floxed HMGCR mice, loxP sites were introduced on either side of exons 12 and 14 of Hmgcr. Adipoq-Cre BAC transgenic mice, in which Cre recombinase is specifically expressed in adipose tissue, were used to cross floxed HMGCR mice (HMGCR f/f) ( Figure S1A) to generate HMGCR f/+ Cre+ progeny. These mice were then backcrossed to HMGCR f/f mice. The backcrossed HMGCR f/+ Cre+ mice were subsequently interbred to yield four derivative strains: (i)
HMGCR f/f (Ctrl), (ii) HMGCR f/f Cre+ (aKO), (iii) HMGCR f/+ Cre+ (heterogeneous aKO), and (iv) HMGCR f/+. aKO mice were predicted to have adipose-specific loss of Hmgcr exons 12-14, which was expected to abolish translation of the entire carbohydroxylation site (Asn 281) containing the catalytic activity (Liscum et al., 1985) .
Adipose Tissue Implantation
The adipose tissue implantation was performed as previous study . To prevent rejection, donors and recipients were sex-matched. Five-week-old C57BL/6J mice were used as fat donors. Donor adipose tissues from euthanized C57BL/6J mice were placed into sterile phosphate-buffered saline and cut into 100-to 150-mg pieces. The fat grafts were implanted subcutaneously in the shaved skin of the backs of anesthetized 8-week-old aKO mice via small incisions. Into two incisions, 3 to 4 fat grafts were placed, totaling 1000 mg of fat per mouse. After surgery, mice were housed individually for 2 weeks.
Cell culture
Two days after reaching confluence (D0), 3T3-L1 cells were incubated in a differentiation medium containing 0.25 μM dexamethazone, 10 μg/ml insulin, and 0.5 mM 3-isobutyl-1-methylxanthine in the growth medium. After 48 h (D2), the cell culture medium was changed to post differentiation medium containing 5 μg/ml insulin in the growth medium, and a fresh post-differentiation medium was also supplied at Day 4 (D4). At 4 days after differentiation, 3T3-L1 cells were used for subsequent experiments. To increase the efficiency of adenovirus-regulated transduction of short hairpin RNA (shRNA), 3T3-L1 adipocytes stably expressing coxsackie-adenovirus receptor (CAR)-L1 were obtained (Ito et al., 2007) .
Four days after differentiation, CAR-L1 cells were re-seeded into a new plate and infected with adenovirus encoding Ggps-specific shRNA or with control adenovirus encoding lacZ, for additional 4 days. The target sequences were as follows: Ggps#1, 5ʹ-GGAACCGTCAGCTTTGAAATTTA-3ʹ; Ggps#2, 5ʹ-GTCCAACTGAAGAAGAATATAAA-3ʹ;
Ggps#3, 5ʹ-CAGCTGTTCTCTGATTACAAAGA-3ʹ; lacZ control, 5ʹ-GCTACACAAATCAGCGATTT-3ʹ.
ERT2-Cre-infected HMGCR f/f primary WAT cells were differentiated by a method consistent with that used for 3T3-L1 cells. For lipid staining, the adipocytes were double-stained with 10 μg/ml Nile red and 20 μM Hoechst 33324. For apoptosis staining, the Annexin V-FITC Apoptosis Detection Kit (Nacalai Tesque) was used in accordance with the manufacturer's instructions.
Histological Analysis
The organ samples of BAT, iWAT, eWAT, and the liver were fixed in 4% paraformaldehyde. The fixed samples were embedded in paraffin for staining with eosin Y (Wako Pure Chemicals) or embedded in O.C.T. compound (Sakura
Finetek Japan, Tokyo, Japan) for staining with Oil Red O. Both eosin Y-and Oil Red O-stained cells were counterstained with modified Mayer's hematoxylin (Merck, Darmstadt, Germany).
Hepatic Lipid Analysis
To quantify hepatic TG content, the lipids were extracted by 1.2 ml of hexane/2-propanol (3:2 v/v) for each 50 mg of liver samples. The liver samples were homogenized and centrifuged at 4 °C for 10 min at 10,000 ´g. After drying by evaporation, the lipid extracts were resuspended in 2-propanol and determined enzymatically using the TG E-test (Wako Pure Chemicals).
Hepatic Glycogen Analysis
Eppendorf tubes containing 600 μl of 30% (W/V) KOH were used to extract 100 mg of each liver sample, followed by incubation at 100 °C until the sample dissolved. Then, 100 μl of saturated Na2SO4 and 750 μl of 95% EtOH were added and vortexed, and then incubated at 100°C until small bubbles were confirmed. The samples were centrifuged at 4°C for 10 min at 300 ´g, and the supernatant was decanted to dry the samples. Then, 400 μl of distilled water and 500 μl of 95% EtOH were added to all samples and mixed. After incubation at 100°C until small bubbles formed, the samples were centrifuged at 4°C and 300 ´g for 10 min. The samples were then decanted and dried, and 1.2 ml of 0.6 N HCl was added with incubation at 100 °C for 2 to 2.5 hours. From each sample, 300 μl was removed to a new Eppendorf tube containing 415 μl of 0.5 N NaOH and 285 μl of distilled water and mixed. The concentration of the samples was measured by glucose C-test.
Analysis of Plasma Chemical Parameters
The levels of glucose, TG, cholesterol, β-HB, FFA, GOT/GPT, leptin, insulin, and adiponectin were determined using commercially available kits: glucose C-test, triacylglycerol E-test, cholesterol E-test, autokit 3-HB, NEFA C-test, transaminase C-test (Wako Pure Chemicals), mouse/rat leptin ELISA kit, ultrasensitive mouse insulin assay kit (Morinaga Institute of Biologic Science, Yokohama, Japan), and mouse adiponectin/Acrp30 Quantikine ELISA kit
